Does TACROLIMUS Cause Diffuse large b-cell lymphoma recurrent? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.0% of all adverse event reports for TACROLIMUS.
11
Reports of Diffuse large b-cell lymphoma recurrent with TACROLIMUS
0.0%
of all TACROLIMUS reports
6
Deaths
8
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From TACROLIMUS?
Of the 11 reports, 6 (54.5%) resulted in death, 8 (72.7%) required hospitalization, and 1 (9.1%) were considered life-threatening.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Product use in unapproved indication (5,057)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which TACROLIMUS Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB